Brief: Ocumension Therapeutics Posts FY Adjusted Net Loss Non-IFRS Adjustment RMB187.0 Mln
25/03/2022 13:38
March 25 (Reuters) - Ocumension Therapeutics 1477.HK :
* FY ADJUSTED NET LOSS NON-IFRS ADJUSTMENt RMB187.0 MILLION
VERSUS
RMB276.7 MILLION
* FY REVENUE RMB56.1 MILLION VERSUS RMB13.1 MILLION
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application